Cyclerion Therapeutics (CYCN) Invested Capital (2019 - 2021)

Cyclerion Therapeutics has reported Invested Capital for 3 years, with the latest figure at $48.2 million in Q4 2021.

• On a quarterly basis, Invested Capital fell 23.77% year-over-year to $48.2 million in Q4 2021; TTM through Dec 2021 was $48.2 million, a 23.77% decrease from a year earlier, with the FY2021 full-year figure at $48.2 million, down 23.77% from the prior year.
• Invested Capital was $48.2 million for Q4 2021 at Cyclerion Therapeutics, down from $59.9 million in the prior quarter.
• The five-year high for Invested Capital was $143.1 million in Q2 2019, with the low at $48.2 million in Q4 2021.
• Average Invested Capital over 3 years is $80.3 million, with a median of $70.0 million recorded in 2020.
• The sharpest annual moves came in 2020 and 2021: Invested Capital slumped 51.1% in 2020, then retreated 1.79% in 2021.
• Over 3 years, Invested Capital stood at $97.8 million in 2019, then sank by 35.29% to $63.3 million in 2020, then dropped by 23.77% to $48.2 million in 2021.
• The last three Invested Capital figures came in at $48.2 million (Q4 2021), $59.9 million (Q3 2021), and $68.7 million (Q2 2021), per Business Quant data.